Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Jun;33(6):797–800. doi: 10.1128/aac.33.6.797

Aminoglycoside-induced hearing loss in humans.

R E Brummett 1, K E Fox 1
PMCID: PMC284232  PMID: 2669624

Full text

PDF
797

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apgar D. A. Comment on aminoglycoside evaluation. Drug Intell Clin Pharm. 1982 Dec;16(12):956–961. doi: 10.1177/106002808201601212. [DOI] [PubMed] [Google Scholar]
  2. Bailey R. R. The aminoglycosides. Drugs. 1981 Oct;22(4):321–327. doi: 10.2165/00003495-198122040-00004. [DOI] [PubMed] [Google Scholar]
  3. Ballantyne J. Ototoxicity. J Laryngol Otol Suppl. 1983;8:9–12. [PubMed] [Google Scholar]
  4. Barza M., Lauermann M. W., Tally F. P., Gorbach S. L. Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity. Antimicrob Agents Chemother. 1980 Apr;17(4):707–714. doi: 10.1128/aac.17.4.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barza M., Lauermann M. Why monitor serum levels of gentamicin? Clin Pharmacokinet. 1978 May-Jun;3(3):202–215. doi: 10.2165/00003088-197803030-00002. [DOI] [PubMed] [Google Scholar]
  6. Bauer M., Zanon E., Balogh D., Rauchegger H. Schwerhörigkeit, eine Komplikation der Antibiotikatherapie bei Schwerverbrannten. Handchir Mikrochir Plast Chir. 1987 May;19(3):125–128. [PubMed] [Google Scholar]
  7. Bernard P. A., Péchère J. C., Hébert R. Altered objective audiometry in aminoglycosides-treated human neonates. Arch Otorhinolaryngol. 1980;228(3):205–210. doi: 10.1007/BF00454229. [DOI] [PubMed] [Google Scholar]
  8. Black F. O., Johnson J. T., Effron M. Z., Burns D. S., Wall C., 3rd Vestibular ototoxicity of prophylactic aminoglycoside antibiotics in head and neck cancer patients. Otolaryngol Head Neck Surg. 1982 May-Jun;90(3 Pt 1):349–354. [PubMed] [Google Scholar]
  9. Bock B. V., Edelstein P. H., Meyer R. D. Prospective comparative study of efficacy and toxicity of netilmicin and amikacin. Antimicrob Agents Chemother. 1980 Feb;17(2):217–225. doi: 10.1128/aac.17.2.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Boffman J. H. Hearing can be lost during healing. Issues Compr Pediatr Nurs. 1984;7(2-3):131–139. doi: 10.3109/01460868409009051. [DOI] [PubMed] [Google Scholar]
  11. Brown R. D., Henley C. M., Penny J. E., Kupetz S. Link between functional and morphological changes in the inner ear--functional changes produced by ototoxic agents and their interactions. Arch Toxicol Suppl. 1985;8:240–250. doi: 10.1007/978-3-642-69928-3_36. [DOI] [PubMed] [Google Scholar]
  12. Bégué P., Safran C., Quiniou F., Michel B., Laget P. Dibekacin in the newborn: pharmacokinetics and evaluation of ototoxicity in neonates and premature infants. Dev Pharmacol Ther. 1984;7 (Suppl 1):116–120. doi: 10.1159/000457239. [DOI] [PubMed] [Google Scholar]
  13. Catlin F. I. Prevention of hearing impairment from infection and ototoxic drugs. Arch Otolaryngol. 1985 Jun;111(6):377–384. doi: 10.1001/archotol.1985.00800080063007. [DOI] [PubMed] [Google Scholar]
  14. Crass R. E. Gentamicin-induced ototoxicity in a carefully monitored renal-failure patient. Am J Hosp Pharm. 1981 Apr;38(4):540–545. [PubMed] [Google Scholar]
  15. Crifo S., Antonelli M., Gagliardi M., Lucarelli N., Marcolini P. Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis. Int J Pediatr Otorhinolaryngol. 1980 Sep;2(3):251–253. doi: 10.1016/0165-5876(80)90050-6. [DOI] [PubMed] [Google Scholar]
  16. D'Alonzo B. J., Cantor A. B. Ototoxicity: etiology and issues. J Fam Pract. 1983 Mar;16(3):489–494. [PubMed] [Google Scholar]
  17. Davey P. G., Jabeen F. J., Harpur E. S., Shenoi P. M., Geddes A. M. A controlled study of the reliability of pure tone audiometry for the detection of gentamicin auditory toxicity. J Laryngol Otol. 1983 Jan;97(1):27–36. doi: 10.1017/s0022215100093762. [DOI] [PubMed] [Google Scholar]
  18. Davey P. G., Jabeen F., Harpur E. S., Shenoi P. M., Geddes A. M. The use of pure-tone audiometry in the assessment of gentamicin auditory toxicity. Br J Audiol. 1982 May;16(2):151–154. doi: 10.3109/03005368209081462. [DOI] [PubMed] [Google Scholar]
  19. De Jongh C. A., Joshi J. H., Thompson B. W., Newman K. A., Finley R. S., Moody M. R., Salvatore P. C., Tenney J. H., Drusano G. L., Schimpff S. C. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1986 May 30;80(5C):101–111. [PubMed] [Google Scholar]
  20. Echeverria P., Fina D., Norton S., Smith A. L. Ototoxicity of gentamicin: clinical experience in a children's hospital. Chemotherapy. 1978;24(4):267–271. doi: 10.1159/000237791. [DOI] [PubMed] [Google Scholar]
  21. Evans D. A., Buring J., Mayrent S., Rosner B., Colton T., Hennekens C. Qualitative overview of randomized trials of aminoglycosides. Am J Med. 1986 Jun 30;80(6B):39–43. doi: 10.1016/0002-9343(86)90477-8. [DOI] [PubMed] [Google Scholar]
  22. Federspil P. Drug-induced sudden hearing loss and vestibular disturbances. Adv Otorhinolaryngol. 1981;27:144–158. doi: 10.1159/000400337. [DOI] [PubMed] [Google Scholar]
  23. Fee W. E., Jr, Vierra V., Lathrop G. R. Clinical evaluation of aminoglycoside toxicity: tobramycin versus gentamicin, a preliminary report. J Antimicrob Chemother. 1978 May;4 (Suppl A):31–36. doi: 10.1093/jac/4.suppl_a.31. [DOI] [PubMed] [Google Scholar]
  24. Finitzo-Hieber T., McCracken G. H., Jr, Brown K. C. Prospective controlled evaluation of auditory function in neonates given netilmicin or amikacin. J Pediatr. 1985 Jan;106(1):129–136. doi: 10.1016/s0022-3476(85)80485-6. [DOI] [PubMed] [Google Scholar]
  25. Follath F., Wenk M., Vozeh S. Plasma concentration monitoring of aminoglycosides. J Antimicrob Chemother. 1981 Jul;8 (Suppl A):37–43. doi: 10.1093/jac/8.suppl_a.37. [DOI] [PubMed] [Google Scholar]
  26. Fong I. W., Fenton R. S., Bird R. Comparative toxicity of gentamicin versus tobramycin: a randomized prospective study. J Antimicrob Chemother. 1981 Jan;7(1):81–88. doi: 10.1093/jac/7.1.81. [DOI] [PubMed] [Google Scholar]
  27. Forrey A. W., Meijsen-Ludwick B. T., O'Neill M. A., Maxwell B. M., Blair A. D., Cutler R. E. Nephrotoxicity: a comparison in humans of gentamicin and gentamicin C1 administration. Toxicol Appl Pharmacol. 1978 Jun;44(3):453–462. doi: 10.1016/0041-008x(78)90253-3. [DOI] [PubMed] [Google Scholar]
  28. Gailiunas P., Jr, Dominguez-Moreno M., Lazarus M., Lowrie E. G., Gottlieb M. N., Merrill J. P. Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy. Arch Intern Med. 1978 Nov;138(11):1621–1624. doi: 10.1001/archinte.138.11.1621. [DOI] [PubMed] [Google Scholar]
  29. Gatell J. M., Ferran F., Araujo V., Bonet M., Soriano E., Traserra J., SanMiguel J. G. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother. 1987 Sep;31(9):1383–1387. doi: 10.1128/aac.31.9.1383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gatell J. M., SanMiguel J. G., Araujo V., Zamora L., Maña J., Ferrer M., Bonet M., Bohe M., Jimenez de Anta M. T. Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin. Antimicrob Agents Chemother. 1984 Nov;26(5):766–769. doi: 10.1128/aac.26.5.766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Guay D. R. Netilmicin (Netromycin, Schering-Plough). Drug Intell Clin Pharm. 1983 Feb;17(2):83–91. doi: 10.1177/106002808301700201. [DOI] [PubMed] [Google Scholar]
  32. Guerit J. M., Mahieu P., Houben-Giurgea S., Herbay S. The influence of ototoxic drugs on brainstem auditory evoked potentials in man. Arch Otorhinolaryngol. 1981;233(2):189–199. doi: 10.1007/BF00453643. [DOI] [PubMed] [Google Scholar]
  33. Gundersen B. Drug-induced ototoxicity. Conn Med. 1986 Apr;50(4):267–268. [PubMed] [Google Scholar]
  34. Hall J. W., 3rd, Herndon D. N., Gary L. B., Winkler J. B. Auditory brainstem response in young burn-wound patients treated with ototoxic drugs. Int J Pediatr Otorhinolaryngol. 1986 Dec;12(2):187–203. doi: 10.1016/s0165-5876(86)80075-1. [DOI] [PubMed] [Google Scholar]
  35. Herting R. L., Lane A. Z., Lorber R. R., Wright J. J. Netilmicin: chemical development and overview of clinical research. Scand J Infect Dis Suppl. 1980;Suppl 23:20–29. [PubMed] [Google Scholar]
  36. Holm S. E., Hill B., Löwestad A., Maller R., Vikerfors T. A prospective, randomized study of amikacin and gentamicin in serious infections with focus on efficacy, toxicity and duration of serum levels above the MIC. J Antimicrob Chemother. 1983 Oct;12(4):393–402. doi: 10.1093/jac/12.4.393. [DOI] [PubMed] [Google Scholar]
  37. Honrubia V., Marco J., Andrews J., Minser K., Yee R. D., Baloh R. W. Vestibulo-ocular reflexes in peripheral labyrinthine lesions: III. Bilateral dysfunction. Am J Otolaryngol. 1985 Sep-Oct;6(5):342–352. doi: 10.1016/s0196-0709(85)80011-9. [DOI] [PubMed] [Google Scholar]
  38. Jackson G. G. Clinical assessment of newer antibiotics. Effect in compromised hosts and drug combinations. Scand J Infect Dis Suppl. 1980;Suppl 23:167–175. [PubMed] [Google Scholar]
  39. Johnson J. T., Kamerer D. B. Aminoglycoside ototoxicity. An update, with implications for all drug therapies. Postgrad Med. 1985 Apr;77(5):131-4, 138. doi: 10.1080/00325481.1985.11698953. [DOI] [PubMed] [Google Scholar]
  40. Johnsson L. G., Hawkins J. E., Jr, Kingsley T. C., Black F. O., Matz G. J. Aminoglycoside-induced cochlear pathology in man. Acta Otolaryngol Suppl. 1981;383:1–19. [PubMed] [Google Scholar]
  41. Kahalley S., Chandler J., Hawkins J., Norris G., Waugespack R., Snow R. M. Prospective, randomized comparison of the efficacy and safety of netilmicin-clindamycin and tobramycin-clindamycin in the treatment of serious systemic infections. Clin Ther. 1985;7(4):497–506. [PubMed] [Google Scholar]
  42. Kahlmeter G., Dahlager J. I. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984 Jan;13 (Suppl A):9–22. doi: 10.1093/jac/13.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  43. Keene M., Graham J. M. Clinical monitoring of the effects of gentamicin by electrocochleography. J Laryngol Otol. 1984 Jan;98(1):11–21. doi: 10.1017/s0022215100146110. [DOI] [PubMed] [Google Scholar]
  44. Kumor K. M., McDonald J. M., Lietman P. S. Effect of 'high-dose' amikacin in children. Dev Pharmacol Ther. 1984;7(6):368–376. doi: 10.1159/000457188. [DOI] [PubMed] [Google Scholar]
  45. Lau W. K., Young L. S., Black R. E., Winston D. J., Linne S. R., Weinstein R. J., Hewitt W. L. Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. Am J Med. 1977 Jun;62(6):959–966. doi: 10.1016/0002-9343(77)90669-6. [DOI] [PubMed] [Google Scholar]
  46. Lerner S. A., Matz G. J. Aminoglycoside ototoxicity. Am J Otolaryngol. 1980 Feb;1(2):169–179. doi: 10.1016/s0196-0709(80)80012-3. [DOI] [PubMed] [Google Scholar]
  47. Lerner S. A., Schmitt B. A., Seligsohn R., Matz G. J. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med. 1986 Jun 30;80(6B):98–104. doi: 10.1016/0002-9343(86)90486-9. [DOI] [PubMed] [Google Scholar]
  48. Levin S., Karakusis P. H. Future trends in aminoglycoside therapy. Am J Med. 1986 Jun 30;80(6B):190–194. doi: 10.1016/0002-9343(86)90500-0. [DOI] [PubMed] [Google Scholar]
  49. Lorber R. R., Linzmayer M. I. Netilmicin in the treatment of Pseudomonas bacteremia. Clin Ther. 1985;7(3):338–346. [PubMed] [Google Scholar]
  50. Luft F. C. Netilmicin: a review of toxicity in laboratory animals. J Int Med Res. 1978;6(4):286–299. doi: 10.1177/030006057800600406. [DOI] [PubMed] [Google Scholar]
  51. Matz G. J. Aminoglycoside ototoxicity. Am J Otolaryngol. 1986 Mar-Apr;7(2):117–119. doi: 10.1016/s0196-0709(86)80040-0. [DOI] [PubMed] [Google Scholar]
  52. Matz G. J., Lerner S. A., Lanzl E. F. Aminoglycoside antibiotics in the treatment of otologic infections. Otolaryngol Head Neck Surg. 1981 Sep-Oct;89(5):705–709. doi: 10.1177/019459988108900501. [DOI] [PubMed] [Google Scholar]
  53. McCracken G. H., Jr Aminoglycoside toxicity in infants and children. Am J Med. 1986 Jun 30;80(6B):172–178. doi: 10.1016/0002-9343(86)90497-3. [DOI] [PubMed] [Google Scholar]
  54. Moffat D. A., Ramsden R. T. Profound bilateral sensorineural hearing loss during gentamicin therapy. J Laryngol Otol. 1977 Jun;91(6):511–516. doi: 10.1017/s0022215100083985. [DOI] [PubMed] [Google Scholar]
  55. Moore R. D., Smith C. R., Lietman P. S. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984 Jan;149(1):23–30. doi: 10.1093/infdis/149.1.23. [DOI] [PubMed] [Google Scholar]
  56. Mukherjee D. K., Mukherjee K. Ototoxicity of commonly used pharmaceutical preparations. Niger Med J. 1979 Jan;9(1):52–57. [PubMed] [Google Scholar]
  57. Nordström L., Christensson P., Haeger K., Juhlin I., Tjernström O., Wallmark E. Netilmicin: clinical evaluation of efficacy and toxicity of a new aminoglycoside. J Int Med Res. 1979;7(2):117–126. doi: 10.1177/030006057900700202. [DOI] [PubMed] [Google Scholar]
  58. Parini R., Rusconi F., Cavanna G., Vigliani E., Cornacchia L., Assael B. M. Evaluation of the renal and auditory function of neonates treated with amikacin. Dev Pharmacol Ther. 1982;5(1-2):33–46. [PubMed] [Google Scholar]
  59. Pedersen S. S., Jensen T., Osterhammel D., Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother. 1987 Apr;31(4):594–599. doi: 10.1128/aac.31.4.594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Peitersen E. Aminoglycoside-ototoxicity. The role of investigational technique and the influence of patient condition on test results. Scand J Infect Dis Suppl. 1980;Suppl 23:114–116. [PubMed] [Google Scholar]
  61. Perera M. R., Amirak I. D., Noone P. Netilmicin 200 mg twice a day for adult patients with life-threatening infections. A preliminary report. Scand J Infect Dis Suppl. 1980;Suppl 23:186–188. [PubMed] [Google Scholar]
  62. Pien F. D., Ho P. W. Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate. Am J Hosp Pharm. 1981 Jul;38(7):981–989. [PubMed] [Google Scholar]
  63. Proctor L., Petty B., Thakor R., Lietman P., Glackin R., Shimizu H. A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin. Laryngoscope. 1987 Dec;97(12):1443–1449. doi: 10.1288/00005537-198712000-00012. [DOI] [PubMed] [Google Scholar]
  64. Ramsden R. T., Ackrill P. Bobbing oscillopsia from gentamicin toxicity. Br J Audiol. 1982 May;16(2):147–150. doi: 10.3109/03005368209081461. [DOI] [PubMed] [Google Scholar]
  65. Rankin E. M., Jones D. M., Lawston F. G., Kane R. J., Scarffe J. H. Observations on the toxicity of the combination of gentamicin and mezlocillin in the treatment of patients with acute leukaemia. J Antimicrob Chemother. 1984 Oct;14(4):411–421. doi: 10.1093/jac/14.4.411. [DOI] [PubMed] [Google Scholar]
  66. Rappaport B. Z., Fausti S. A., Schechter M. A., Frey R. H. A prospective study of high-frequency auditory function in patients receiving oral neomycin. Scand Audiol. 1986;15(2):67–71. doi: 10.3109/01050398609045956. [DOI] [PubMed] [Google Scholar]
  67. Ristuccia A. M., Cunha B. A. An overview of amikacin. Ther Drug Monit. 1985;7(1):12–25. doi: 10.1097/00007691-198503000-00003. [DOI] [PubMed] [Google Scholar]
  68. Ristuccia A. M., Cunha B. A. The aminoglycosides. Med Clin North Am. 1982 Jan;66(1):303–312. doi: 10.1016/s0025-7125(16)31462-6. [DOI] [PubMed] [Google Scholar]
  69. SATALOFF J., WAGNER S., MENDUKE H. KANAMYCIN OTOTOXICITY IN HEALTHY MEN. Arch Otolaryngol. 1964 Oct;80:413–417. doi: 10.1001/archotol.1964.00750040425010. [DOI] [PubMed] [Google Scholar]
  70. Sage R., Nazareth B., Noone P. A prospective randomised comparison of cefotaxime vs. netilmicin vs. cefotaxime plus netilmicin in the treatment of hospitalised patients with serious sepsis. Scand J Infect Dis. 1987;19(3):331–337. doi: 10.3109/00365548709018479. [DOI] [PubMed] [Google Scholar]
  71. Smith C. R., Ambinder R., Lipsky J. J., Petty B. G., Israel E., Levitt R., Mellits E. D., Rocco L., Longstreth J., Lietman P. S. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial. Ann Intern Med. 1984 Oct;101(4):469–477. doi: 10.7326/0003-4819-101-4-469. [DOI] [PubMed] [Google Scholar]
  72. Smith C. R., Baughman K. L., Edwards C. Q., Rogers J. F., Lietman P. S. Controlled comparison of amikacin and gentamicin. N Engl J Med. 1977 Feb 17;296(7):349–353. doi: 10.1056/NEJM197702172960701. [DOI] [PubMed] [Google Scholar]
  73. Smith C. R., Lipsky J. J., Laskin O. L., Hellmann D. B., Mellits E. D., Longstreth J., Lietman P. S. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980 May 15;302(20):1106–1109. doi: 10.1056/NEJM198005153022002. [DOI] [PubMed] [Google Scholar]
  74. Smith C. R., Lipsky J. J., Lietman P. S. Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Antimicrob Agents Chemother. 1979 Jun;15(6):780–782. doi: 10.1128/aac.15.6.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Tablan O. C., Reyes M. P., Rintelmann W. F., Lerner A. M. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis. J Infect Dis. 1984 Feb;149(2):257–263. doi: 10.1093/infdis/149.2.257. [DOI] [PubMed] [Google Scholar]
  76. Tjernström O., Denneberg T., Harris S., Nordström L., Toremalm N. G. Ototoxicity of netilmicin. Acta Otolaryngol. 1982 Nov-Dec;94(5-6):421–429. doi: 10.3109/00016488209128930. [DOI] [PubMed] [Google Scholar]
  77. Tjernström O. Prospective evaluation of vestibular and auditory function in 76 patients treated with netilmicin. Scand J Infect Dis Suppl. 1980;Suppl 23:122–125. [PubMed] [Google Scholar]
  78. Vesterhauge S., Johnsen N. J., Thomsen J., Svare J. Netilmicin treatment followed by monitoring of vestibular and auditory function using highly sensitive methods. Scand J Infect Dis Suppl. 1980;Suppl 23:117–121. [PubMed] [Google Scholar]
  79. Walby A. P., Kerr A. G. Streptomycin sulphate and deafness: a review of the literature. Clin Otolaryngol Allied Sci. 1982 Feb;7(1):63–68. doi: 10.1111/j.1365-2273.1982.tb01563.x. [DOI] [PubMed] [Google Scholar]
  80. Ward K. M., Rounthwaite F. J. Neomycin ototoxicity. Ann Otol Rhinol Laryngol. 1978 Mar-Apr;87(2 Pt 1):211–215. doi: 10.1177/000348947808700211. [DOI] [PubMed] [Google Scholar]
  81. Wersäll J. Recent otological evaluation of aminoglycoside antibiotics. J Antimicrob Chemother. 1984 Jan;13 (Suppl A):31–36. doi: 10.1093/jac/13.suppl_a.31. [DOI] [PubMed] [Google Scholar]
  82. Whelton A. Therapeutic initiatives for the avoidance of aminoglycoside toxicity. J Clin Pharmacol. 1985 Mar;25(2):67–81. doi: 10.1002/j.1552-4604.1985.tb02805.x. [DOI] [PubMed] [Google Scholar]
  83. Worning A. M., Frimodt-Møller N., Ostri P., Nilsson T., Højholdt K., Frimodt-Møller C. Antibiotic prophylaxis in vascular reconstructive surgery: a double-blind placebo-controlled study. J Antimicrob Chemother. 1986 Jan;17(1):105–113. doi: 10.1093/jac/17.1.105. [DOI] [PubMed] [Google Scholar]
  84. Yee G. C., Evans W. E. Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. Pharmacotherapy. 1981 Jul-Aug;1(1):55–75. doi: 10.1002/j.1875-9114.1981.tb03553.x. [DOI] [PubMed] [Google Scholar]
  85. Yoshikawa T. T. Proper use of aminoglycosides. Am Fam Physician. 1980 May;21(5):125–130. [PubMed] [Google Scholar]
  86. Yu V. L., Rhame F. S., Pesanti E. L., Axline S. G. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms. JAMA. 1977 Aug 29;238(9):943–947. doi: 10.1001/jama.238.9.943. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES